PGR positive
|
Uterine Corpus Leiomyosarcoma
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
PGR positive
|
HER2 Negative Breast Cancer
|
PGR positive
|
HER2 Negative Breast Cancer
|
anastrozole Sensitive: A2 - Guideline
|
anastrozole Sensitive: A2 - Guideline
|
PGR positive
|
HER2 Negative Breast Cancer
|
PGR positive
|
HER2 Negative Breast Cancer
|
letrozole Sensitive: A2 - Guideline
|
letrozole Sensitive: A2 - Guideline
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
medroxyprogesterone Sensitive: A2 - Guideline
|
medroxyprogesterone Sensitive: A2 - Guideline
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
megestrol Sensitive: A2 - Guideline
|
megestrol Sensitive: A2 - Guideline
|
PGR positive
|
HER2 Positive Breast Cancer
|
PGR positive
|
HER2 Positive Breast Cancer
|
trastuzumab Sensitive: B - Late Trials
|
trastuzumab Sensitive: B - Late Trials
|
PGR positive
|
Uterine Cancer
|
PGR positive
|
Uterine Cancer
|
anastrozole Sensitive: C2 – Inclusion Criteria
|
anastrozole Sensitive: C2 – Inclusion Criteria
|
PGR positive
|
HER2 Positive Breast Cancer
|
PGR positive
|
HER2 Positive Breast Cancer
|
AC Sensitive: C3 – Early Trials
|
AC Sensitive: C3 – Early Trials
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
PGR positive
|
Uterine Corpus Leiomyosarcoma
|
anastrozole Sensitive: C3 – Early Trials
|
anastrozole Sensitive: C3 – Early Trials
|
PGR positive
|
HER2 Negative Breast Cancer
|
PGR positive
|
HER2 Negative Breast Cancer
|
Aromatase inhibitor Sensitive: C3 – Early Trials
|
Aromatase inhibitor Sensitive: C3 – Early Trials
|